The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

Alan L. Hillman, J. Sanford Schwartz, Mary Kaye Willian, Ellen Peskin, Claus Roehrborn, Joseph E. Oesterling, Michael F. Mason, Clem J. Maurath, Patricia A. Deverka, Robert J. Padley

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objectives. To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha1-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH). Methods. Prospective, randomized, double-blind, placebo-controlled multicenter trial of 2084 patients was conducted at 15 academic regional centers and 141 community-based satellite centers. Information about the use of health care resources and nondisease-specific functional status measures was collected by a standardized telephone interview of patients at baseline and every month thereafter for 12 months. Other information, such as American Urologic Association (AUA) disease-specific functional status scores, was obtained from the patient study records. Patients had a mean age of 65.7 years (range, 46 to 94), with a clinical diagnosis of BPH. At baseline men had at least moderate BPH symptoms by AUA Symptom Score (13 or more) and Bother Score (8 or more). On entry, patients at regional sites had peak urinary flow rates 15 mL/s or less and total voided urine volumes 150 mL or greater. A total of 1053 patients were randomized to terazosin and 1031 to placebo treatment. Primary outcome measures included payments for all direct medical resource consumption (inpatient care, emergency department care, outpatient care, and medications); changes in three AUA disease-specific functional status indicators (Symptom, Bother, and Quality of Life scores), and nondisease-specific functional status measures (days of work loss, days of customary activity loss, and days of bed rest). Results. Total payments for health care resources (including study drug medication), adjusted to reflect 1000 patients per treatment group, were $3,781,803 and $3,568,263 in the placebo and terazosin groups, respectively. All three AUA disease-specific functional status scores improved significantly more in the terazosin group than in the placebo group. We found no difference between terazosin and placebo in all three nonspecific functional status measures. Conclusions. Compared with placebo, terazosin therapy for moderate to severe symptomatic BPH results in approximately equivalent payments for direct medical care, better disease-specific functional status improvement, and comparable change in nondisease-specific functional status measures.

Original languageEnglish (US)
Pages (from-to)169-177
Number of pages9
JournalUrology
Volume47
Issue number2
DOIs
StatePublished - Feb 1996

Fingerprint

Terazosin
Prostatic Hyperplasia
Cost-Benefit Analysis
Placebos
Urologic Diseases
Health Resources
Therapeutics
Delivery of Health Care
Community Health Centers
Bed Rest
Emergency Medical Services
Ambulatory Care
Adrenergic Receptors
Multicenter Studies
Hospital Emergency Service
Inpatients

ASJC Scopus subject areas

  • Urology

Cite this

Hillman, A. L., Schwartz, J. S., Willian, M. K., Peskin, E., Roehrborn, C., Oesterling, J. E., ... Padley, R. J. (1996). The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. Urology, 47(2), 169-177. https://doi.org/10.1016/S0090-4295(99)80410-5

The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. / Hillman, Alan L.; Schwartz, J. Sanford; Willian, Mary Kaye; Peskin, Ellen; Roehrborn, Claus; Oesterling, Joseph E.; Mason, Michael F.; Maurath, Clem J.; Deverka, Patricia A.; Padley, Robert J.

In: Urology, Vol. 47, No. 2, 02.1996, p. 169-177.

Research output: Contribution to journalArticle

Hillman, AL, Schwartz, JS, Willian, MK, Peskin, E, Roehrborn, C, Oesterling, JE, Mason, MF, Maurath, CJ, Deverka, PA & Padley, RJ 1996, 'The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia', Urology, vol. 47, no. 2, pp. 169-177. https://doi.org/10.1016/S0090-4295(99)80410-5
Hillman, Alan L. ; Schwartz, J. Sanford ; Willian, Mary Kaye ; Peskin, Ellen ; Roehrborn, Claus ; Oesterling, Joseph E. ; Mason, Michael F. ; Maurath, Clem J. ; Deverka, Patricia A. ; Padley, Robert J. / The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. In: Urology. 1996 ; Vol. 47, No. 2. pp. 169-177.
@article{2ccdb014a2bc4b6fa949c8b3565a39da,
title = "The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia",
abstract = "Objectives. To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha1-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH). Methods. Prospective, randomized, double-blind, placebo-controlled multicenter trial of 2084 patients was conducted at 15 academic regional centers and 141 community-based satellite centers. Information about the use of health care resources and nondisease-specific functional status measures was collected by a standardized telephone interview of patients at baseline and every month thereafter for 12 months. Other information, such as American Urologic Association (AUA) disease-specific functional status scores, was obtained from the patient study records. Patients had a mean age of 65.7 years (range, 46 to 94), with a clinical diagnosis of BPH. At baseline men had at least moderate BPH symptoms by AUA Symptom Score (13 or more) and Bother Score (8 or more). On entry, patients at regional sites had peak urinary flow rates 15 mL/s or less and total voided urine volumes 150 mL or greater. A total of 1053 patients were randomized to terazosin and 1031 to placebo treatment. Primary outcome measures included payments for all direct medical resource consumption (inpatient care, emergency department care, outpatient care, and medications); changes in three AUA disease-specific functional status indicators (Symptom, Bother, and Quality of Life scores), and nondisease-specific functional status measures (days of work loss, days of customary activity loss, and days of bed rest). Results. Total payments for health care resources (including study drug medication), adjusted to reflect 1000 patients per treatment group, were $3,781,803 and $3,568,263 in the placebo and terazosin groups, respectively. All three AUA disease-specific functional status scores improved significantly more in the terazosin group than in the placebo group. We found no difference between terazosin and placebo in all three nonspecific functional status measures. Conclusions. Compared with placebo, terazosin therapy for moderate to severe symptomatic BPH results in approximately equivalent payments for direct medical care, better disease-specific functional status improvement, and comparable change in nondisease-specific functional status measures.",
author = "Hillman, {Alan L.} and Schwartz, {J. Sanford} and Willian, {Mary Kaye} and Ellen Peskin and Claus Roehrborn and Oesterling, {Joseph E.} and Mason, {Michael F.} and Maurath, {Clem J.} and Deverka, {Patricia A.} and Padley, {Robert J.}",
year = "1996",
month = "2",
doi = "10.1016/S0090-4295(99)80410-5",
language = "English (US)",
volume = "47",
pages = "169--177",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia

AU - Hillman, Alan L.

AU - Schwartz, J. Sanford

AU - Willian, Mary Kaye

AU - Peskin, Ellen

AU - Roehrborn, Claus

AU - Oesterling, Joseph E.

AU - Mason, Michael F.

AU - Maurath, Clem J.

AU - Deverka, Patricia A.

AU - Padley, Robert J.

PY - 1996/2

Y1 - 1996/2

N2 - Objectives. To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha1-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH). Methods. Prospective, randomized, double-blind, placebo-controlled multicenter trial of 2084 patients was conducted at 15 academic regional centers and 141 community-based satellite centers. Information about the use of health care resources and nondisease-specific functional status measures was collected by a standardized telephone interview of patients at baseline and every month thereafter for 12 months. Other information, such as American Urologic Association (AUA) disease-specific functional status scores, was obtained from the patient study records. Patients had a mean age of 65.7 years (range, 46 to 94), with a clinical diagnosis of BPH. At baseline men had at least moderate BPH symptoms by AUA Symptom Score (13 or more) and Bother Score (8 or more). On entry, patients at regional sites had peak urinary flow rates 15 mL/s or less and total voided urine volumes 150 mL or greater. A total of 1053 patients were randomized to terazosin and 1031 to placebo treatment. Primary outcome measures included payments for all direct medical resource consumption (inpatient care, emergency department care, outpatient care, and medications); changes in three AUA disease-specific functional status indicators (Symptom, Bother, and Quality of Life scores), and nondisease-specific functional status measures (days of work loss, days of customary activity loss, and days of bed rest). Results. Total payments for health care resources (including study drug medication), adjusted to reflect 1000 patients per treatment group, were $3,781,803 and $3,568,263 in the placebo and terazosin groups, respectively. All three AUA disease-specific functional status scores improved significantly more in the terazosin group than in the placebo group. We found no difference between terazosin and placebo in all three nonspecific functional status measures. Conclusions. Compared with placebo, terazosin therapy for moderate to severe symptomatic BPH results in approximately equivalent payments for direct medical care, better disease-specific functional status improvement, and comparable change in nondisease-specific functional status measures.

AB - Objectives. To evaluate the cost-effectiveness and functional status effects of terazosin, an alpha1-adrenoceptor antagonist, compared with placebo in the treatment of men with moderate to severe, symptomatic, benign prostatic hyperplasia (BPH). Methods. Prospective, randomized, double-blind, placebo-controlled multicenter trial of 2084 patients was conducted at 15 academic regional centers and 141 community-based satellite centers. Information about the use of health care resources and nondisease-specific functional status measures was collected by a standardized telephone interview of patients at baseline and every month thereafter for 12 months. Other information, such as American Urologic Association (AUA) disease-specific functional status scores, was obtained from the patient study records. Patients had a mean age of 65.7 years (range, 46 to 94), with a clinical diagnosis of BPH. At baseline men had at least moderate BPH symptoms by AUA Symptom Score (13 or more) and Bother Score (8 or more). On entry, patients at regional sites had peak urinary flow rates 15 mL/s or less and total voided urine volumes 150 mL or greater. A total of 1053 patients were randomized to terazosin and 1031 to placebo treatment. Primary outcome measures included payments for all direct medical resource consumption (inpatient care, emergency department care, outpatient care, and medications); changes in three AUA disease-specific functional status indicators (Symptom, Bother, and Quality of Life scores), and nondisease-specific functional status measures (days of work loss, days of customary activity loss, and days of bed rest). Results. Total payments for health care resources (including study drug medication), adjusted to reflect 1000 patients per treatment group, were $3,781,803 and $3,568,263 in the placebo and terazosin groups, respectively. All three AUA disease-specific functional status scores improved significantly more in the terazosin group than in the placebo group. We found no difference between terazosin and placebo in all three nonspecific functional status measures. Conclusions. Compared with placebo, terazosin therapy for moderate to severe symptomatic BPH results in approximately equivalent payments for direct medical care, better disease-specific functional status improvement, and comparable change in nondisease-specific functional status measures.

UR - http://www.scopus.com/inward/record.url?scp=9044236517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044236517&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(99)80410-5

DO - 10.1016/S0090-4295(99)80410-5

M3 - Article

C2 - 8607228

AN - SCOPUS:9044236517

VL - 47

SP - 169

EP - 177

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -